Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
957 ^USD	+2.07%		+8.36%	+8.96%

May. 03	Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept	MT
May. 03	Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
Sector Update: Health Care Stocks Mixed Premarket Thursday	May. 02	MT
Regeneron: Adjusted EPS down 4% in Q1	May. 02	CF
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 3, 2023.	May. 02	CI
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales	May. 02	DJ
Regeneron Pharmaceuticals' Q1 Non-GAAP Net Income, Revenue Decline	May. 02	MT
Regeneron Pharmaceuticals, Inc. announces an Equity Buyback for $3,000 million worth of its shares.	May. 02	CI
Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn	May. 02	MT
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 Revenue $3.15B, vs. Street Est of $3.22B	May. 02	MT
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 EPS $9.55, vs. Street Est of $10.10	May. 02	MT
Regeneron misses profit estimates on weaker Eylea and Dupixent sales	May. 02	RE
Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says	Apr. 26	MT
Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences	Apr. 25	DJ
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation Crispr-Based Gene Editing for Multiple Diseases	Apr. 25	CI
Sanofi Q1 profit slips on generic competition, forex effects	Apr. 25	RE
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	Apr. 23	MT
The market is pinning its hopes on earnings reports	Apr. 17
Regeneron to defend against DOJ complaint on drug-price manipulation	Apr. 15	RE
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation	Apr. 15	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Highlights

Filters